Rezon Bio announces that its Warsaw-Duchnice facility has received approval from the U.S. Food and Drug Administration (FDA) for the commercial manufactu...
CRO expands oncology, adds functional service provider capabilities, strengthens global reach, and accelerates technology to enhance customer value ...
The Seattle facility of AGC Biologics, your friendly CDMO expert, has received a Good Manufacturing Practices Certification from Agência Nacional d...
Leading GMP cell therapy CDMO I Peace, Inc., specializing in induced pluripotent stem cells (iPSCs) and iPSC-derived cell therapies, announced that it ha...
Ardena, a specialist CDMO and bioanalytical CRO enabling precision medicines and other complex therapies, today announced that it has completed the dives...
SK Capital Partners have signed a definitive agreement to divest the Noramco API related assets in a sale to Siegfried (Zofingen Switzerland) The...
Gannet BioChem, a leading specialty Contract Development and Manufacturing Organization (CDMO) backed by Boston-based private equity firm Ampersand Capit...
HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseas...
Charles River Laboratories International, Inc. (NYSE: CRL) and Gazi University Faculty of Medicine, announced a gene therapy contract developme...
Rakuten Medical, Inc. and LOTTE Biologics announced that they have signed a biopharmaceutical contract manufacturing agreement during the J.P....
Jubilant Biosys Limited, a wholly owned subsidiary of Jubilant Pharmova Limited, and a global CRDMO operating from five sites across India ...
Charles River Laboratories’ announcement of a planned leadership transition marks one of the most consequential succession moments in the global pr...
Transcenta Holding Limited (HKEX: 06628) (“Transcenta Therapeutics”), a global clinical stage biopharmaceutical company with fully-inte...
Houston-area clinical research organization Hope Biosciences Research Foundation (HBRF) shares positive top-line results of a Phase II clinical tri...
© 2026 Biopharma Boardroom. All Rights Reserved.
